期刊文献+

GLP-1Ra减少高糖诱导的β细胞凋亡作用机制探讨 被引量:6

Glucagon-like peptide 1 receptor agonist protects high-glucose induced β cells apoptosis via inhibition of NOX2-dependent ROS production
下载PDF
导出
摘要 目的探讨胰高血糖素样肽-1(GLP-1)受体激动剂(GLP-1Ra)减少高糖诱导的β细胞凋亡作用的可能机制。方法正常对照(N,普通饲料喂养)组、2型糖尿病(T2DM)组和GLP-1 Ra组[利拉鲁肽200μg/(kg·d)]大鼠干预12周。比较各组大鼠造模前、造模后给药前(0周)及12周末血糖水平。高压液相色谱分析法测定糖化血红蛋白(Hb A1c);全自动生化分析仪测定天冬氨酸转氨酶(AST)、肌酐(CR)及尿素氮(BUN)等;TUNEL染色观察胰岛细胞凋亡情况;免疫组化法测定cleaved caspase 3;DCFH-DA荧光探针检测胰岛活性氧簇(ROS);免疫组织化学法检测NADPH氧化酶(NOX)催化亚基(NOX2)。结果 12周时,GLP-1Ra组的血糖、Hb A1c、总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-c)水平均低于T2DM组(P<0.05);GLP-1Ra组胰岛细胞凋亡率和cleaved caspase 3水平较T2DM组下降(P<0.05);应用Apocynin抑制前,GLP-1Ra组胰岛ROS水平明显低于T2DM组,并与N组差异无统计学意义(P>0.05),应用Apocynin抑制后,各组间差异均无统计学意义(P>0.05)。GLP-1Ra组胰岛NOX2水平较T2DM组下降(P<0.05)。结论 GLP-1Ra能抑制糖尿病大鼠β细胞的凋亡,抑制NOX2来源的ROS产生可能是重要的潜在机制之一。 Objective To investigate the possible mechanisms of glucagon-like peptide 1 receptor agonists (GLP- 1Ra) protection against hyperglycemic induced beta cell apoptosis through depression of NOX2-dependent ROS production. Methods The rat model of type 2 diabetes (T2DM) was established by injecting small doses of streptozotocin (STZ) fol- lowed by 8-week high fat diet. The experimental animals were divided into three groups: normal control (N) group, diabetes (T2DM) group and GLP-IRa group [treated with liraglutide 200 μg/(kg, d) for 12 weeks]. The blood glucose levels were compared before and after modeling, before treatment and 12-week after treatment with GLP- 1Ra. The level of glycosylated hemoglobin (HbAlc) was detected by high-pressure liquid chromatography. Automatic biochemical analyzer was used to detect levels of aspertate aminotransferase (AST), creatinine (CR) and urea nitrogen (BUN). The apoptotic rates of islets were determined by TUNEL method and cleaved caspase 3 was detected by immunohistochemistry. DCFH-DA fluorescent probe was used to detect reactive oxygen species (ROS) levels of islets. Levels of NADPH oxidase (NOX) catalytic subunit (NOX2) in islets were measured by immunohistochemistry. Results At the end of the study, glycemic control (average blood glucose/ week and HbAlc) and lipid situation were improved significantly in the GLP-IRa group than those of N group (P〈 0.05). TUNEL staining and displayed that β cell apoptotic and cleaved caspase 3 level were significantly decreased in GLP-IRa group compared to those of T2DM group (P 〈 0.05). ROS levels were significantly decreased in GLP- 1Ra group than those of T2DM group before treatment with Apocynin, but no significant difference between GLP1-Ra group and N group (P 〉 0.05). After application Apocynin for inhibition, there were no significant differences between three groups (P 〉 0.05). The level of NOX2 was significantly lower in GLP- 1Ra group compared to that of T2DM group (P 〈 0.05). Conclusion GLP- IRa can inhibit apoptosis of β cells in diabetes rat, and the depression of NOX2-dependent ROS may be one of the important underlying mechanisms.
出处 《天津医药》 CAS 2015年第11期1217-1221,I0001,共6页 Tianjin Medical Journal
基金 国家自然科学基金青年科学基金项目(81300663) 天津市卫生局科技基金(2013KZ098)
关键词 糖尿病 2型 疾病模型 动物 胰高糖素样肽-1 NOX2 氧化应激 凋亡 利拉鲁肽 活性氧簇 diabetes , type 2 disease models, animal Glucagon-like peptide- 1 NOX2 oxidative stress apoptosis liraglutide ROS
  • 相关文献

参考文献17

  • 1Kim, JY, Lim DM, Moon CI, et al. Exendin-4 protects oxidative stress-induced beta-cell apoptosis through reduced JNK and GSK3beta activity[J]. J Korean Med Sci, 2010,25(11): 1626-1632. doi: 10.3346/jkms.2010.25.11.1626.
  • 2Jiao J, Dou L, Li M, et al. NADPH oxidase 2 plays a critical role in dysfunction and apoptosis of pancreatic beta-cells induced by very low-density lipoprotein[J]. Mol Cell Biochem, 2012,370(1-2): 103- 113. doi: 10.1007/s11010-012-1402-z.
  • 3Emmens RW, Baylan U, Naaijkens B, et al.The GLP-1 analogue li- raglutide decreases the pro-inflammatory status of the heart in dia- betes[J]. Eur Heart J, 2013,34: 1755,.
  • 4Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and in- creased beta-cell apoptosis in humans with type 2 diabetes[J]. Dia- betes, 2003, 52(1): 102-110.doi: 10.2337/diabetes.52.1.102.
  • 5Henry RR, Buse JB, Sesti G, et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(lc): a meta- analysis of the liraglutide development program[J]. Endocr Pract, 2011,17(6): 906-913.
  • 6Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically rele- vant composite outcome of an HbAlc of <7% without weight gain or hypoglycaemia in type 2 diabetes: a recta-analysis of the liraglutide clinical trim programme[J]. Diabetes Obes Metab, 2012, 14(1): 77- 82. doi: 0.1111/j. 1463-1326.2011.01493.x.
  • 7Vilsbll T, Brock B, Perrild H, et al. Liraglutide, a once-daily hu- man GLP-1 analogue, improves pancreatic B-cell function and ar- ginine-stimulated insulin secretion during hyperglycaemia in pa- tients with type 2 diabetes mellitus[J]. Diabet Med, 2008, 25(2): 152-156.doi: 10.1111/j.1464-5491.2007.02333.x.
  • 8Li CJ, Yu Q, Yu P, et al. Changes in liraglutide-induced body com- position are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients[J]. Cardiovasc Dia- betol, 2014, 13: 36.doi: 10.1186/1475-2840-13-36.
  • 9Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabe- tes (LEAD- 1 SU) [J]. Diabet Med, 2009, 26(3): 268-278.doi: 10.1111/j. 1464-5491.2009.02666.x.
  • 10Du Q, Wang YJ, Yang S,et al. Liraglutide for the treatment of type 2 diabetes mellitus: a meta- analysis of randomized placebo- con-trolled trials[J]. Adv Ther, 2014,31(11): 1182-1195. doi: 10.1007/ s12325-014-0164-2.

同被引文献69

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部